Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients

Table 1

Factors influencing IBD quality of life.

		Univariate analysis	Multivariate model: backward elimination
Variables	435	Unadjusted OR; Risk of having pathological IBDQ (≤170)	Adjusted OR; Risk of having pathological IBDQ (≤170)	Adjusted OR; Risk of having pathological IBDQ (≤170)
Disease
CD	203	1	1	1
UC	232	0.59 (0.40-0.88)	0.44 (0.28-0.71)	0.44 (0.28-0.70)
Age group
<45	189	1
≥45	246	1.19 (0.80-1.76)
Sex
Men	231	1
Women	204	1.20 (0.81-1.76)
Disease latency
≤1 year	335	1
>1 year	100	1.03 (0.96-1.11)
Disease duration
≤5 years	80	1
>5 years	355	0.99 (0.97-1.01)
Current smoking status
Nonsmoker	371	1
Smoker	64	0.17 (0.68-2.01)
Current alcohol intake
No	189	1	1
Yes	246	0.63 (0.42-0.92)	0.69 (0.44-1.07)
Disease active ( or )
Inactive	332	1	1	1
Active	103	5.62 (3.47-9.12)	5.47 (3.11-9.61)	5.67 (3.30-9.76)
High faecal calprotectin (>250)
No	248	1	1
Yes	187	1.90 (1.28-2.82)	1.18 (0.74-1.87)
Anaemia (, <13 males)
No	373	1	1	1
Yes	62	2.69 (1.68-5.80)	2.05 (1.09-3.86)	2.15 (1.15-4.03)
UC localization
E1/E2	123	1
E3	109	1.34 (0.77-2.33)
CD behavior
Nonstricturing, nonpenetrating	104	1
Stricturing	65	1.01 (0.54-1.89)
Penetrating	34	1.26 (0.58-2.73)
Localization
L1 terminal ileum	48	1
L2 colon or L3 ileocolon	148	1.19 (0.61-2/29)
L4 upper or upper+other	7	1.86 (0.37-9.27)
Extraintestinal manifestations
No	326	1	1	1
Yes	109	3.89 (2.47-6.14)	3.08 (1.87-5.08)	3.15 (1.92-5.18)
Immunosuppressant
No	381	1
Yes	54	1.19 (0.67-2.12)
Biologics
No	262	1
Yes	173	1.42 (0.96-2.10)
Surgery
No	320	1
Yes	115	1.36 (0.88-2.10)